166 related articles for article (PubMed ID: 19138933)
21. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
Kowalczyk M; Orłowski M; Klepacki Ł; Zinkiewicz K; Kurpiewski W; Kaczerska D; Pesta W; Zieliński E; Siermontowski P
BMC Cancer; 2020 Feb; 20(1):133. PubMed ID: 32075595
[TBL] [Abstract][Full Text] [Related]
22. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon.
Paulsen JE; Steffensen IL; Løberg EM; Husøy T; Namork E; Alexander J
Cancer Res; 2001 Jul; 61(13):5010-5. PubMed ID: 11431334
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
[TBL] [Abstract][Full Text] [Related]
24. Chemoprevention of arylamine-induced colorectal aberrant crypts.
Feng Y; Neale JR; Doll MA; Hein DW
Exp Biol Med (Maywood); 2008 Jan; 233(1):71-5. PubMed ID: 18156308
[TBL] [Abstract][Full Text] [Related]
25. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Chan AT; Hsu M; Zauber AG; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2012 Jan; 5(1):61-72. PubMed ID: 22030088
[TBL] [Abstract][Full Text] [Related]
26. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
[TBL] [Abstract][Full Text] [Related]
27. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
[No Abstract] [Full Text] [Related]
28. Beta-catenin expression is altered in human colonic aberrant crypt foci.
Hao XP; Pretlow TG; Rao JS; Pretlow TP
Cancer Res; 2001 Nov; 61(22):8085-8. PubMed ID: 11719432
[TBL] [Abstract][Full Text] [Related]
29. Aberrant crypt foci as microscopic precursors of colorectal cancer.
Cheng L; Lai MD
World J Gastroenterol; 2003 Dec; 9(12):2642-9. PubMed ID: 14669304
[TBL] [Abstract][Full Text] [Related]
30. Aberrant crypt foci: what we know and what we need to know.
Gupta AK; Pretlow TP; Schoen RE
Clin Gastroenterol Hepatol; 2007 May; 5(5):526-33. PubMed ID: 17433788
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
[TBL] [Abstract][Full Text] [Related]
33. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
34. A multicenter study of prevalence and risk factors for aberrant crypt foci.
Mutch MG; Schoen RE; Fleshman JW; Rall CJ; Dry S; Seligson D; Charabaty A; Chia D; Umar A; Viner J; Hawk E; Pinsky PF
Clin Gastroenterol Hepatol; 2009 May; 7(5):568-74. PubMed ID: 19418605
[TBL] [Abstract][Full Text] [Related]
35. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
36. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Chan AT; Sima CS; Zauber AG; Ridker PM; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1172-80. PubMed ID: 21816845
[TBL] [Abstract][Full Text] [Related]
37. Modulation of aberrant crypt foci by dietary fat and caloric restriction: the effects of delayed intervention.
Lasko CM; Bird RP
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):49-55. PubMed ID: 7894324
[TBL] [Abstract][Full Text] [Related]
38. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
39. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
Wang J; Carvajal-Carmona LG; Chu JH; Zauber AG; ; Kubo M; Matsuda K; Dunlop M; Houlston RS; Sieber O; Lipton L; Gibbs P; Martin NG; Montgomery GW; Young J; Baird PN; Ratain MJ; Nakamura Y; Weiss ST; Tomlinson I; Bertagnolli MM
Clin Cancer Res; 2013 Dec; 19(23):6430-7. PubMed ID: 24084763
[TBL] [Abstract][Full Text] [Related]
40. Aberrant crypt focus size predicts distal polyp histopathology.
Kim J; Ng J; Arozulllah A; Ewing R; Llor X; Carroll RE; Benya RV
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1155-62. PubMed ID: 18483337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
